Developing serum proteomics based prediction models of disease progression in ADPKD

Abstract Autosomal Dominant Polycystic Kidney Disease is the most common genetic cause of kidney failure. Outcome prediction is essential to guide therapeutic decisions. However, currently available models are of limited accuracy. We aimed to examine the potential of serum proteomics for improved ri...

Full description

Saved in:
Bibliographic Details
Main Authors: Hande Ö. Aydogan Balaban, Sita Arjune, Franziska Grundmann, Jan-Wilm Lackmann, Thomas Rauen, Philipp Antczak, Roman-Ulrich Müller
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61887-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234970673938432
author Hande Ö. Aydogan Balaban
Sita Arjune
Franziska Grundmann
Jan-Wilm Lackmann
Thomas Rauen
Philipp Antczak
Roman-Ulrich Müller
author_facet Hande Ö. Aydogan Balaban
Sita Arjune
Franziska Grundmann
Jan-Wilm Lackmann
Thomas Rauen
Philipp Antczak
Roman-Ulrich Müller
author_sort Hande Ö. Aydogan Balaban
collection DOAJ
description Abstract Autosomal Dominant Polycystic Kidney Disease is the most common genetic cause of kidney failure. Outcome prediction is essential to guide therapeutic decisions. However, currently available models are of limited accuracy. We aimed to examine the potential of serum proteomics for improved risk stratification. Here we show that 29 proteins are significantly associated with yearly kidney function decline. Functional enrichment on these 29 proteins reveals GO:BP terms related to immune response, lipoproteins and metabolic processes. A comparison to an Immunoglobulin A nephropathy cohort provides information regarding the eGFR-dependency and disease specificity of these proteins. The final outcome prediction model (adjusted R² 0.31) contains six proteins, namely Endothelial Plasminogen Activator Inhibitor (SERPINF1), Glutathione Peroxidase 3 (GPX3), Afamin (AFM), FERM Domain Containing Kindlin-3 (FERMT3), Complement Factor H Related 1 (CFHR1), and Retinoic Acid Receptor Responder 2 (RARRES2), the predictive value of which is independent from the clinical and imaging parameters currently used in clinical care. The validation of these models in different cohorts indicates the accuracy of the models. It will now be important to move towards targeted validation in a prospective study.
format Article
id doaj-art-0c4508a826ad4e6fa2625d6e7376d205
institution Kabale University
issn 2041-1723
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-0c4508a826ad4e6fa2625d6e7376d2052025-08-20T04:02:56ZengNature PortfolioNature Communications2041-17232025-07-0116111110.1038/s41467-025-61887-8Developing serum proteomics based prediction models of disease progression in ADPKDHande Ö. Aydogan Balaban0Sita Arjune1Franziska Grundmann2Jan-Wilm Lackmann3Thomas Rauen4Philipp Antczak5Roman-Ulrich Müller6Department II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital CologneDepartment II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital CologneDepartment II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital CologneCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne and University Hospital CologneDepartment of Nephrology and Clinical Immunology, RWTH Aachen University HospitalDepartment II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital CologneDepartment II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital CologneAbstract Autosomal Dominant Polycystic Kidney Disease is the most common genetic cause of kidney failure. Outcome prediction is essential to guide therapeutic decisions. However, currently available models are of limited accuracy. We aimed to examine the potential of serum proteomics for improved risk stratification. Here we show that 29 proteins are significantly associated with yearly kidney function decline. Functional enrichment on these 29 proteins reveals GO:BP terms related to immune response, lipoproteins and metabolic processes. A comparison to an Immunoglobulin A nephropathy cohort provides information regarding the eGFR-dependency and disease specificity of these proteins. The final outcome prediction model (adjusted R² 0.31) contains six proteins, namely Endothelial Plasminogen Activator Inhibitor (SERPINF1), Glutathione Peroxidase 3 (GPX3), Afamin (AFM), FERM Domain Containing Kindlin-3 (FERMT3), Complement Factor H Related 1 (CFHR1), and Retinoic Acid Receptor Responder 2 (RARRES2), the predictive value of which is independent from the clinical and imaging parameters currently used in clinical care. The validation of these models in different cohorts indicates the accuracy of the models. It will now be important to move towards targeted validation in a prospective study.https://doi.org/10.1038/s41467-025-61887-8
spellingShingle Hande Ö. Aydogan Balaban
Sita Arjune
Franziska Grundmann
Jan-Wilm Lackmann
Thomas Rauen
Philipp Antczak
Roman-Ulrich Müller
Developing serum proteomics based prediction models of disease progression in ADPKD
Nature Communications
title Developing serum proteomics based prediction models of disease progression in ADPKD
title_full Developing serum proteomics based prediction models of disease progression in ADPKD
title_fullStr Developing serum proteomics based prediction models of disease progression in ADPKD
title_full_unstemmed Developing serum proteomics based prediction models of disease progression in ADPKD
title_short Developing serum proteomics based prediction models of disease progression in ADPKD
title_sort developing serum proteomics based prediction models of disease progression in adpkd
url https://doi.org/10.1038/s41467-025-61887-8
work_keys_str_mv AT handeoaydoganbalaban developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT sitaarjune developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT franziskagrundmann developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT janwilmlackmann developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT thomasrauen developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT philippantczak developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd
AT romanulrichmuller developingserumproteomicsbasedpredictionmodelsofdiseaseprogressioninadpkd